J. Mcintyre, J. Castaǹer, M. Bayes
2003
Citations
0
Influential Citations
2
Citations
Journal
Drugs of The Future
Abstract
Peroxisome proiiferator-activated receptors (PPARs) modulate gene expression in the process of lipid metabolism. Tesaglitazar is a novel, dual PPAR agonist which binds to and activates both α and γ recepfor subtypes with similar high potency. It is currently being developed for the treatment of insulin resist -, - -related glucose and lipid abnormalities associated with type 2 diabetes and the metabolic syndrome. in rodent models of insulin resistance, tesaglitazar has been shown to improve insulin sensitity and to have beneficial effects on fatty acid and glucose metabolism. In nondiabetic subjects with abnormalities charr acteristic of insulin resistance, there were significant dose-dependent reductions in fasting triglycerides, glucose and insulin in subjects treated with tesaglilazar. The drug is currently in phase III trials.